Introduction
Osteoarthritis (OA) is the most common form of arthritis. OA is charact erized by progressive articular cartil age loss, appositional new bone formation with sclerosis and abnormal vascularization of subchondraltrabeculae and plate, and formation of osteophytes [1] [2] [3] . Synovitis is often observed and is considered secondary to changes in hard tissues within the joint. The widely held belief that OA is a disease of articular cartilage, with cartilage erosion being the main identifying feature, has been a subject for debate, particularly in recent years, and several investigations have led to the postulation that bone changes may account for subsequent joint deterioration and development of OA. OA risk factors in humans include age, gender, genetic predisposition, mechanical stress and/or joint trauma, and obesity 4, 5 . Bone mass in OA patients is better preserved 6 than in healthy individuals, independently of body weight. Moreover, increase in bone mass is noted for both the usually affected sites, such as the knee and the hip, as well as non-synovial sites, such as the lumbar spine. Genetic studies indicate a recessively inherited gene and a multifactorial component. Hence, the 'gene' is more likely to express a factor involved in a metabolic pathway than a structural skeletal protein. Studies examining a metabolic link between obesity and OA have reported con licting indings. Some studies were able to show a signi icant association between hypertension, uric acid, cholesterol and OA, whereas others failed to substantiate these relationships 7, 8 . Therefore, a unifying hypothesis taking into account all features of pathology could be that OA is a metabolic disease in which systemic and/or local factors induce changes in skeletal tissues by modifying the formation and biosynthetic activity of cells derived from mesenchymal stem cell (MSC). As tissue homeostasis is disturbed and joint integrity impaired, normal wear and tear could then lead to cartilage damage, the hallmark of OA. The loss of cartilage may then be a result of mechanical forces, but this would not cause the disease itself. Furthermore, OA process may modify the formation and biosynthetic activity of MSC 9 . In as much as adipocytes share a common MSC precursor with osteoblasts (Ob), chondrocytes, tenocytes and myoblasts, all cells affected by OA, a link between lipid metabolism and connective tissues is probable. Such a link may be related to leptin, a known factor involved in body weight regulation and obesity, and in lipid metabolism. Leptin causes the local differentiation of mesenchymal stromal cells into Ob within the bone marrow, while impeding the maturation of adipocytes 10 . Indeed, Ob increases in proportion to an increase in adipocytes and chondrocytes and is blunted by using bone marrow stromal cells from OA patients 11 , therefore implying a key role for leptin in this process. The activity of the Wnt/β-catenin signalling pathway is also crucial for the recruitment and differentiation of MSC into osteoblasts and adipocytes. Indeed, β-catenin levels must vary within a narrow limit at speci ic time points during MSC, pre-Ob and Ob development. This critical review discusses OA and the rationale for a new paradigm shift involving transforming growth factor-β1 (TFG-β1).
Discussion
The authors have referenced some of their own studies in this review. These referenced studies have been conducted in accordance with the Declaration of Helsinki (1964) , and the protocols of these studies have been approved by relevant ethics committees related to the institutions Osteoarthritis: rationale for a new paradigm shift involving transforming growth factor-a1 in which they were performed. All human subjects in these referenced studies gave informed consent to participate in these studies.
What are the causes of abnormal subchondral bone remodelling in OA?
Abnormal indices of bone remodelling are observed in OA patients 12 , and in animal models with spontaneous OA [13] [14] [15] . Indeed, increased subchondral bone activity in OA, as judged by enhanced uptake of technetium labelled diphosphonate, predicts cartilage loss, and cartilage lesions do not progress without signi icant subchondral activity 16 . Alterations of the bony bed precede cartilage changes in the Macacafascicularis primate model of OA 17, 18 and in the Dunkin-Hartley guinea pig model 15 . This is associated with intensi ied remodelling of the subchondral bone and increased bone stiffness 19 , which results in the bone no longer being an effective shock absorber 20, 21 . In addition, bone is not the only dense tissue in joints. Indeed, the calci ied cartilage tissue is also dense and even more so in OA calci ied tissue, hence probably not providing a tissue of intermediate stiffness under these conditions 22 . However, subchondral bone stiffness in OA may be part of a more generalized bone alteration leading to an apparent increased bone mineral density (BMD) or bone volume as observed in most obese individuals. An extremely hypermineralized articular calci ied cartilage and subchondral bone tissue of femoral heads can be observed by quantitative backscattered electron imaging in OA patients 23 . Such a localized increase in BMD was con irmed using Fourier transform infrared spectroscopy of OA knee joints, suggesting that this is related to a remineralization of the subchondral bone tissue 24 . In addition, BMD of the subchondraltibial bone correlates with progressive joint space narrowing in knee OA 23 and with osteophytes 25 . Increased bone density and osteoid volume are often more severe than cartilage changes in animal models of spontaneous OA 17, 18 . However, an apparent increase in BMD in OA may be due to an increase in material density and need not result from an increase in mineral density caused by increased osteoid collagen matrix that is undermineralized 12, 26, 27 . Such an increase of osteoid volume in OA bone tissue 28 is also an indication of abnormal mineralization. OA bone's hardness is 7% lower than that of osteoporotic bone, indicating that OA bone has a reduced elastic modulus 29 . These results support the view of a more generalized bone metabolic disease in OA [30] [31] [32] and that alteration of subchondral bone integrity is a key event in OA 33 .
Evidence for a role of abnormal bone cell metabolism in OA
A high body mass index (BMI) as observed in OA patients is linked with a higher bone mass, and increased BMD suggests new bone synthesis exceeds degradation in OA. Indeed, elevated osteocalcin serum levels in women with hand OA and in cortical bone explants 32 , and the observation that insulin-like growth factors (IGF-I and II) and TGF-β levels are higher in samples of iliac crest bone of patients with OA 34 , hence at a site distant from weight-bearing joints, suggest an increased bone anabolism in OA. Moreover, an imbalance between collagen and non-collagen protein synthesis like osteocalcin can lead to an increase in bone volume without a concomitant increase in BMD. Abnormal collagen content may also lead to abnormal mineralization as only native collagen type I ibrils can mineralize. Intriguingly, collagen type I is elevated in trabecular bone of femoral heads of OA patients 12 , and leptin can directly stimulate the synthesis of the a1 chain of collagen type 1 in in vitro Obs 26 . However, collagen type I is composed of an heterotrimer of a1 and a2 chains at an average ratio of 2.4:1 in normal bone, yet this varied between 4:1 and 17:1 in OA bone tissue 27 . In vivo, the increase in bone collagen matrix could also be linked to altered MSC differentiation into Obs, since in OA patients Obs maturation from bone marrow stromal cells is enhanced while that of adipocytes and chondrocytes is blunted 11 .
Role of MSCs in OA
The potential role of bone tissue in OA initiation or progression may be due to its capacity to serve as a reservoir for MSCs and to provide nutrition of the hyaline cartilage. 40 , alterations in the differentiation capacity of MSC to form myocytes may also be altered in these individuals, which was never demonstrated however. The alteration in OA MSC may also affect the important immunoregulatory role played by MSC. This regulatory role is modulated by speci ic signalling molecules such as TGF-β1 and hepatocyte growth factor (HGF) . Hence, it is important to remember the key role played by cytokines and growth factors in osteophyte formation, the elevation of TGF-β1 41 and HGF levels in OA cartilage 42, 43 , and elevated messenger RNA (mRNA) and protein levels of both TGF-β1 41, 44 and HGF 42 in OA osteoblasts. MSC isolated from adipose tissue secrete HGF that can decrease TGF-β1 production in co-cultures with chondrocytes, indicating another potential crosstalk between different joint tissues 45 . Osteophyte formation may be considered a repair response to stabilize the damaged joints, and it requires the local recruitment of speci ic MSC 46 . Under normal conditions, local TGF-β1 levels are kept at a normal level in response to shear stress in synovial membranes, whereas OA could be viewed as an exaggerated response to shear stress or a continued response to leading to abnormally high levels of TGF-β1 47 . This could alter the Wnt signalling pathway triggered in MSC and lead to abnormal recruitment of pre-Ob and Ob at the expense of chondrocytes and adipocytes.
Role of the Wnt signalling pathway in MSC lineage commitment
Wnt signalling plays a crucial role in MSC self-renewal in adult tissues 48 . MSCs serve as a reservoir for tissue renewal following trauma, disease and aging. Via its interaction with frizzled (Fz) and LRP5/6 co-receptors, Wnts inactivate the axin-GSK3β complex. This latter complex phosphorylates and drives the degradation of β-catenin, whereas Wnts inhibit this activity. 62 . This suggests that the balance of these Wnts and Wnt antagonists (and other signals probably) in OA bone could prevent adipogenesis while promoting the recruitment of osteoprogenitors. In addition, this imbalance in Wnts and Wnt antagonists may also contribute to alter the terminal differentiation Ob, that is, the expression of abnormal phenotype markers and mineralization 44, 63 .
Role of TGF-β1 in cartilage and bone tissue: involvement in OA pathogenesis TGF-β1 plays a dual role in skeletal tissues. Although it is an essential anabolic growth factor for cartilage growth and as such used in vitro for cartilage bioengineering, it can also cause OA-like features upon prolonged exposure. TGF-β1 also drives osteophyte formation. Early observations of OA bone tissue samples reported increased levels of TGF-β1 and IGF-1 even in non-weight-bearing joints, implying that OA could be a bone disease. Moreover, TGF-β1 levels remain elevated in isolated bone explants and in vitro osteoblasts of OA patients 41, 44 . A recent study indicated that targeted overexpression of TGF-β1 in mouse osteoblasts, but not in other joint tissues, lead to OA-like features, whereas inhibition of TGF-β1 activity in subchondral bone prevented the degeneration of articular cartilage in these mice 64 . osteoblasts leads to the alteration of Wnt signalling targets and abnormal release of secreted factors involved in MSC recruitment. This observation is reminiscent of those previously made using targeted overexpression of TGF/bone morphogenetic protein (BMP) inhibitors that reduced osteophyte formation and disease progression in an induced OA mouse model 65 . This would concur with previous observations of alterations of TGF-β1 production in human OA bone tissue and osteoblasts 30, 41, 44 . Our recent observation that the activity of Wnt/β-catenin signalling is reduced in human OA Ob compared to normal due to an elevated expression of the Wnt antagonist Dickkopft-2 (DKK2) is therefore timely 44 . Moreover, TGF-β1 drives DKK2 expression in human OA Ob (44), and they both inhibit Ob mineralization 63 as it occurs in human OA bone tissue 12, 27 . As the aforesaid deleterious effects of TGF-β1 are driven via the ALK5 receptor pathway, which triggers SMAD2/3, it was suggested that direct intervention on this signalling route could be bene icial for OA. This can now be reconciled with the anabolic role of TGF-β1 in cartilage. In chondrocytes, TGF-β1 induces tissue inhibitors of metalloproteinases (TIMP), counteracts the in lammatory role played by IL-1, and can prevent hypertrophy, a chondrocyte phenotype found in OA, via the SMAD2/3 pathway. Altered SMAD3 expression may be possible in OA as single-nucleotide polymorphisms (SNPs) have been observed in populations of Northern Europe and China affected by OA 66, 67 , whereas abnormal SMAD3 expression and abnormal relationship with bone mineralization have been observed in OA versus normal bone tissue and osteoblasts 68 . For the European study, genetic variation in the Smad3 gene has been associated with knee and hip OA A (66) . Unfortunately, this study does not identify whether these mutations could induce a gain or loss of function. Therefore, targeting the anaplastic lymphoma kinase (ALK5) pathway for treating OA may still be complicated. Of note, recent studies have indicated that reduced SMAD2/3 activity could be detrimental to cartilage 69 and prolonged exposure to TGF-β1 can drive SMAD1/5/8 after interacting with ALK1. This triggers MMP-13, which is a potent driving force for the loss of articular cartilage. This shift in ALK5 towards ALK1 activity is observed not only in aging but also in OA pathogenesis, implying that ALK1 would be a more interesting target for therapeutic intervention regarding cartilage, whereas this route does not seem to play a key role in bone 70 . Moreover, as abnormal TGF-β1 levels alter not only cartilage but also MSC recruitment and differentiation, it would be important to more closely understand factor(s) involved in this paracrine signalling. Although the authors suggested Wnts or Wnt targets could be involved, more input is de initely needed to determine which factor(s) are involved. Among potential hypotheses, we cannot overlook that obesity is a high-risk factor for developing OA 4,5 , and leptin has been pointed out as a key factor in obesity. Leptin, the product of the obese (ob) gene, is a 16-kDa protein produced by white adipocytes and other cells such as skeletal muscles 71 and osteoblasts 72 . Leptin favours the local differentiation of MSC into Ob within the bone marrow while impeding the maturation of adipocytes (10) , an effect reminiscent of the observations made with bone-marrow stromal cells from OA patients (11) and implying a key role for leptin in this process. Last, leptin has been shown to promote TGF-β1 expression in joint tissues of rats 73 , and the role of TGF-β1 in OA is now considered a key event in the pathogenesis of this disease 64 , although it is still not known what would trigger TGF-β1 levels locally.
Conclusion
Recent studies have contributed to a shift in our understanding of OA and the causative events that may lead to it. We moved from a general consensus on cartilage disease towards a bona ide bone disease, to a joint disease involving all joints, and now we are progressing to understand that local signals emanating from osteoblasts (possibly chondrocytes, though this has not been tested) trigger abnormal recruitment of MSCs that alter tissue integrity and signal homeostasis. Such a local factor could be TGF-β1, and abnormal active TGF-β1 levels could be achieved via altered metabolic signals such as leptin and shear stress in joint tissues. 
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